Literature DB >> 16350389

The emergency use of recombinant hirudin in cardiopulmonary bypass. 1999.

Nicklett Johnston, Michael E Jessen, Michael DiMaio, Debra S Douglass.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16350389      PMCID： PMC4680795     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN： 0022-1058


× No keyword cloud information.
  10 in total

1.  A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery.

Authors:  F C Riess; B Pötzsch; R Bader; N Bleese; A Greinacher; C Löwer; K Madlener; G Müller-Berghaus
Journal:  Eur J Cardiothorac Surg       Date:  1996       Impact factor: 4.191

2.  Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.

Authors:  B Pötzsch; K Madlener; C Seelig; C F Riess; A Greinacher; G Müller-Berghaus
Journal:  Thromb Haemost       Date:  1997-05       Impact factor: 5.249

3.  Heparin-induced thrombocytopenia: effects of rabbit IgG, and its Fab and FC fragments on antibody-heparin-platelet interaction.

Authors:  B H Chong; P A Castaldi; M C Berndt
Journal:  Thromb Res       Date:  1989-07-15       Impact factor: 3.944

4.  Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man.

Authors:  F C Riess; C Löwer; C Seelig; N Bleese; J Kormann; G Müller-Berghaus; B Pötzsch
Journal:  J Thorac Cardiovasc Surg       Date:  1995-07       Impact factor: 5.209

5.  Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma.

Authors:  G Hafner; K Fickenscher; H J Friesen; H J Rupprecht; U Konheiser; W Ehrenthal; J Lotz; W Prellwitz
Journal:  Thromb Res       Date:  1995-01-15       Impact factor: 3.944

6.  A new approach in monitoring recombinant hirudin during cardiopulmonary bypass.

Authors:  M J Koza; J M Walenga; J Fareed; R Pifarre
Journal:  Semin Thromb Hemost       Date:  1993       Impact factor: 4.180

7.  Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays.

Authors:  M T Nurmohamed; R J Berckmans; W M Morriën-Salomons; F Berends; D W Hommes; J J Rijnierse; A Sturk
Journal:  Thromb Haemost       Date:  1994-11       Impact factor: 5.249

Review 8.  Heparin-associated thrombocytopenia.

Authors:  D J King; J G Kelton
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

9.  DDAVP reduces bleeding during continued hirudin administration in the rabbit.

Authors:  C M Bove; B Casey; V J Marder
Journal:  Thromb Haemost       Date:  1996-03       Impact factor: 5.249

10.  Heparin induced thrombocytopenia. Experiences in 12 heart surgery patients.

Authors:  R Sodian; M Loebe; K F Gorman; H Riess; R Hetzer
Journal:  ASAIO J       Date:  1997 Sep-Oct       Impact factor: 2.872
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.